Cost of lung cancer diagnosis: cost differences between national health system and private sector

2024-7-15

Moving towards single fraction peripheral lung stereotactic body radiation therapy: patient care during and after the global COVID-19 pandemic

2024-7-3

Achieving long-term survival in extensive-stage SCLC: a case report and mini literature review

2024-3-13

Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis

2024-3-13

Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis

2024-2-28

Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC

2024-2-28

Inflammatory parameters in NSCLC with driver mutation

2024-2-28

Bilateral synchronous multiple lung cancer: an emerging problem

2023-12-1

Increased Sympathetic Nervous System Impairs Prognosis in Lung Cancer Patients: A Scoping Review of Clinical Studies

2023-12-1

A retrospective study of ensartinib-treated <i>ALK</i>-positive locally advanced or metastatic NSCLC patients in China

2023-11-7

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence

2023-7-12

Alectinib for treating patients with metastatic <i>ALK</i>-positive NSCLC: systematic review and network metanalysis

2023-5-25

Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience

2023-3-1

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy

2022-12-1

Treatment Considerations for Patients with Advanced Squamous Cell Carcinoma Of the lung: A Plain Language Summary

2022-9-1

Implementing physician education to increase lung cancer screening uptake

2022-6-1

Exceptional response to afatinib in a patient with persistent G719A <i>EGFR</i>-mutant NSCLC

2022-3-1

Enabling patients in effective self-management of breathlessness in lung cancer: the neglected pillar of personalized medicine

2021-12-1

PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

2021-11-26

A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma

2021-9-1

Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data

2021-7-2

Disparities in lung cancer screening rates among the Hispanic/LatinX population

2021-5-26

Lymphadenopathy and granulomas: benignancy of malignancy and differential diagnosis with endobronchial ultrasound-transbronchial needle biopsy 19G needle fine-needle aspiration biopsy

2021-5-26

HER3 expression and MEK activation in non-small-cell lung carcinoma

2021-4-9

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis

2021-3-1

Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform

2021-3-1

Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

2021-2-18

Current clinical trials and patent update on lung cancer: a retrospective review

2021-2-15

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer

2020-11-23

Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform

2020-11-20

Diagnosis and management of small pulmonary atypical carcinoid tumor associated with Cushing syndrome

2020-9-14

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver

2020-9-1

Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer

2020-9-1

Biopsy frequency and complications among lung cancer patients in the United States

2020-8-17

The Role of Palliative Care in the Management of Patients with Lung Cancer

2020-7-29

Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

2020-7-19

Understanding Sex Disparities in Lung Cancer Incidence: are Women more at Risk?

2020-6-22

Lung cancer screening guidelines are clear but are they being followed?

2020-6-22

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer

2020-6-1

Lung Cancer Management Challenges Amidst COVID-19 Pandemic: Hope Lives Here

2020-5-1

Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma

2020-4-27

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung

2020-4-21

Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLC

2020-3-19

Welcome to Volume 9 of <i>Lung Cancer Management</i>

2020-3-1

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

2020-3-1

Status of Correlation Between BMI and Response to Immunocheck-Point Inhibitor in Advanced Non-Small-Cell Lung Cancer

2020-2-25

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis

2020-2-25

Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer

2020-2-21

Chemotherapy and/or Immune Checkpoint Inhibitors in NSCLC First-Line Setting: what is the Best Approach?

2020-2-12

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation

2020-2-6